AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02576574
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants received Gemcitabine 1000 mg/m\^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with carboplatin until disease progression or unacceptable toxicities.
Trial: NCT02576574
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants received Carboplatin area under concentration curve (AUC) 5 mg/mL\*min in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with gemcitabine until disease progression or unacceptable toxicities.
Trial: NCT02576574
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received Cisplatin 75 mg/m\^2 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
Trial: NCT02576574
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC 6 mg/mL\*min by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with pemetrexed, or paclitaxel until disease progression or unacceptable toxicities.
Trial: NCT02576574
Drug: Avelumab Weekly
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks.
Trial: NCT01841723
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT01000623
Drug: venlafaxine
RxNorm normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT04789005
Drug: Phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylephrine 100mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
Trial: NCT00132405
Drug: ALGRX 3268
RxNorm normalized name: ALGRX 1207
DrugBank: ALGRX 1207 (DB06482)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04421105
Drug: Lysergic acid diethylamide (LSD) 5µg
RxNorm normalized name: diethylamine salicylate / flufenamic acid / myrtecaine
DrugBank: Lysergic acid diethylamide (DB04829)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04421105
Drug: Lysergic acid diethylamide (LSD) 10µg
RxNorm normalized name: diethylamine salicylate / flufenamic acid / myrtecaine
DrugBank: Lysergic acid diethylamide (DB04829)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04421105
Drug: Lysergic acid diethylamide (LSD)20 µg
RxNorm normalized name: Lysergic acid diethylamide
DrugBank: Lysergic acid diethylamide (DB04829)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00464698
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received increasing amounts of Duloxetine for 7 weeks.
Trial: NCT02791230
Drug: Tafamidis
RxNorm normalized name: Tafamidis
DrugBank: Tafamidis (DB11644)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Soft gel capsules administered once a day for 60 months
Trial: NCT02243189
Drug: JNJ-43260295
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single nasal dose of JNJ-43260295, 6400 microgram, will be given.
Trial: NCT02243189
Drug: Nasal Allergen Challenge
RxNorm normalized name: catfish allergenic extract
DrugBank: Catfish (DB14758)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be challenged by the nasal route with an appropriate allergen based on skin test reactivity.
Trial: NCT00758420
Drug: Varisolve (Polidocanol Endovenous Microfoam)
RxNorm normalized name: Polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1% polidocanol, up to 15 mL, one treatment session (initially up to 30 ml, reduced to up to 15 ml in Amendment #2)
Trial: NCT00408031
Drug: D-cycloserine
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-cycloserine (DCS , Seromycin) is a broad spectrum antibiotic, in use for over thirty years against tuberculosis, that acts as a partial agonist at the NMDAR-associated GLY site.
Trial: NCT03866746
Drug: Aflibercept Injection
RxNorm normalized name: aflibercept Injection
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Group A;Under complete aseptic conditions; intravitreal aflibercept injections with dose of 2 mg/0.05 mL per injection was given for the patients. Patients were scheduled to receive 3 loading injections at monthly interval. At the 3rd month; further treatment was planned pro re nata (PRN) according to the response. Injections were discontinued when the CMT reached 250 µm or less. If there was no change in the CMT after two consecutive injections; patients shifted to other line of treatment. Reinjection was continued for the other eyes with re-evaluation of the response every month.In group B Patients received the initial 3 monthly loading doses of IVI of aflibercept followed by MPL therapy (within one week after the 3rd injection). Patients were scheduled for follow-up monthly. Injection followed by MPL was then repeated according to the response as in group A.
Trial: NCT02928679
Drug: Liraglutide 3 mg (Saxenda)
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02928679
Drug: Liraglutide 3 mg placebo
RxNorm normalized name: liraglutide 3.6 MG/ML
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03268772
Drug: PLD and IFO
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PLD 30 mg/m2, d1, plus IFO 1.8 g/m2, d1-5
Trial: NCT01292135
Drug: PCI-32765
RxNorm normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 420 mg daily
Trial: NCT01938079
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine will be initiated as a one-time 40 mg bolus of ketamine followed by a continuous intravenous infusion of 5 micrograms/kg/min at the start of ECMO.
Trial: NCT00315640
Drug: Anecortave Acetate Sterile Suspension, 6 mg/mL
DrugBank: Anecortave acetate (DB05288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
Trial: NCT00315640
Drug: Anecortave Acetate Suspension Depot, 30 mg/mL
DrugBank: Anecortave acetate (DB05288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
Trial: NCT00315640
Drug: Anecortave Acetate Sterile Suspension, 60 mg/mL
DrugBank: Anecortave acetate (DB05288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
Trial: NCT03371836
Drug: Clobazam
RxNorm normalized name: Clobazam
DrugBank: Clobazam (DB00349)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clobazam is used as an adjunct medicine for all participants.
Trial: NCT04188405
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04188405
Drug: Ponatinib
RxNorm normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04188405
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT01702207
Drug: Once Daily Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects switched from the tacrolimus twice daily (Prograf®) to the once daily formulation (Advagraf®) to maintain a trough tacrolimus level of 5-8.
Trial: NCT01702207
Drug: Twice Daily Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects are kept on Prograf® which is the Twice Daily Tacrolimus
Trial: NCT02337413
Drug: Polyethylene glycol 3350
RxNorm normalized name: Polyethylene Glycol 3350
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will initially receive three days of high dose PEG3350 treatment (1.5gr/kg up to 100gr maximum) and then will be stepped down to 0.8gr/kg subsequently and tapered accoriding to stool consistency and frequency.
Trial: NCT04104321
Drug: Aramchol free acid
RxNorm normalized name: acid red 337 free acid
DrugBank: Aramchol (DB11860)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aramchol 300 mg BID
Trial: NCT00887601
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose 5 mg donepezil capsules in two of the four treatment periods.
Trial: NCT03443921
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: After eligibility testing as blood tests, contrast-enhanced CT and MRI scan, 3 cycles were administered (1,000 mg/m2 of gemcitabine and 125 mg/m2 of nab-paclitaxel on days 1, 8, and 15 every 28 days).Patients will be reevaluated and curative operation would be attempted if without disease progression.
Trial: NCT00311012
Drug: Aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01917058
Drug: Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This will be a randomized double blind placebo controlled study. Patients will be randomly assigned to abatacept or placebo in a 1:1 ratio based on a computer generated randomization list. The list will be generated prior to study initiation. Based on the randomization list, patients will be assigned to treatment vs. vehicle (provided by BMS) in the order in which they are enrolled. The assignment will be made by study personnel who are not involved in making clinical assessments or evaluations. The patient and the assessing physicians will remain blinded to the treatment assignment for the duration of the study.~Patients will be treated with abatacept 125mg SC self-administered each week. Treatment will be continued for 6 months to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with alopecia areata. Patients will then be followed for an additional 6 months to assess the timing and incidence of relapse.
Trial: NCT00210574
Drug: topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01934166
Drug: Nalmefene 18 mg
DrugBank: Nalmefene (DB06230)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One single oral dose of 18 mg
Trial: NCT01239849
Drug: Atorvastatin, 10mg, 20mg, 40mg
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If initial LDL cholesterol between 100\~ 129mg/dl then starting dose of Atorvastatin is 10mg, 130\~159 mg/dl is 20 mg, 160\~220mg/dl is 40mg.~After 4weeks treatment, if LDL cholesterol is below 100mg/dl then continue starting dose and if not reach below 100mg/dl then titration double dose.~After 4 weeks treatment, recheck the LDL cholesterol
Trial: NCT03037489
Drug: MIV-711
RxNorm normalized name: MIV-711
DrugBank: MIV-711 (DB15599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIV-711 administered orally once daily
Trial: NCT03361137
Drug: Emicizumab
RxNorm normalized name: Emicizumab
DrugBank: Emicizumab (DB13923)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Emicizumab via SC injection at a loading dose 3 mg/kg once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as the participant continues to derive sufficient benefit. Dosing was to be adjusted if the participant had a significant change in body weight.
Trial: NCT03107481
Drug: Hydromorphone
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydromorphone 1mg IV
Trial: NCT03150914
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: mTOR inhibitor or placebo
Trial: NCT00368641
Drug: Extraneal
RxNorm normalized name: Extraneal
DrugBank: Icodextrin (DB00702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periotneal Dialysis
Trial: NCT03556228
Drug: VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
DrugBank: VMD-928 (DB18052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally once daily
Trial: NCT03850574
Drug: Tuspetinib
RxNorm normalized name: Tuspetinib
DrugBank: Tuspetinib (DB15343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily (QD), continuous dosing
Trial: NCT03850574
Drug: Venetoclax Oral Tablet
RxNorm normalized name: venetoclax Oral Tablet
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax will be given to study participants in the Part C tuspetinib plus venetoclax combination treatment group either in 50 mg or 100 mg tablets
Trial: NCT03850574
Drug: Azacitidine for Intravenous Infusion
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine will be given to study participants in Part D as intravenous infusion at a dose of 75 mg/m\^2
Trial: NCT02238509
Drug: Lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).
Trial: NCT03626727
Drug: Sodium Oxybate Oral Solution [Xyrem]
RxNorm normalized name: sodium oxybate Oral Solution [Xyrem]
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xyrem will be given to participants to determine if it is effective in treating post-traumatic narcolepsy and post-traumatic hypersomnia
Trial: NCT04555486
Drug: DCR-PHXC
RxNorm normalized name: DCR-PHXC free acid
DrugBank: Nedosiran (DB17635)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention, drug, DCR-PHXC
Trial: NCT04555486
Drug: Sterile Normal Saline (0.9% NaCl)
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT02238509
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).
Trial: NCT01266811
Drug: Placebo, Velcade and dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Siltuximab 11 mg/kg as 1 hour IV infusion on Day 1 of every cycle
Trial: NCT02318082
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00901849
Drug: Tarceva and Rapamycin
RxNorm normalized name: Tarceva
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tarceva will be administered once a day for 28 days without interruption. THen Rapamycin will be administered, orally twice daily, in combination with the Tarceva for the remainder of the study.
Trial: NCT04448886
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: (iv) fixed dose, administered once per cycle
Trial: NCT04448886
Drug: Sacituzumab Govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: (iv) fixed dose, administered twice per cycle
Trial: NCT03009058
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of Care chemotherapy
Trial: NCT03009058
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard of Care chemotherapy
Trial: NCT03009058
Drug: Folinic Acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of Care chemotherapy
Trial: NCT03009058
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of Care chemotherapy
Trial: NCT03009058
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of Care chemotherapy
Trial: NCT03596502
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exposure to warfarin will be defined as a new prescription for warfarin (ATC B01AA03) at cohort entry date in patients diagnosed with non-valvular atrial fibrillation.
Trial: NCT04563325
Drug: Oral co-amoxiclav or oral dicloxacillin only
RxNorm normalized name: dicloxacillin Oral Capsule
DrugBank: Dicloxacillin (DB00485)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High dose oral treatment followed by standard dose oral treatment
Trial: NCT04563325
Drug: IV ceftriaxon followed by oral co-amoxiclav or oral dicloxacillin
RxNorm normalized name: dicloxacillin Oral Capsule
DrugBank: Dicloxacillin (DB00485)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV treatment followed by standard dose oral treatment
Trial: NCT03573882
Drug: Voxelotor
RxNorm normalized name: Voxelotor
DrugBank: Voxelotor (DB14975)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300mg or 500mg Tablet, Oral, With or Without Food
Trial: NCT01535040
Drug: memantine hydrochloride
RxNorm normalized name: Memantine Hydrochloride
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estimate participation, accrual, adherence, and retention of cancer survivors who smoke and are randomized to receive memantine (10 mg twice daily) or a matching placebo for 12 weeks.
Trial: NCT03178591
Drug: vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT03491059
Drug: C-11 labeled nicotine
RxNorm normalized name: choline C-11
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will vape with e-cigarettes radio-labeled with C-11 nicotine.
Trial: NCT03178591
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03980509
Drug: Curcumin
RxNorm normalized name: Curcumin
DrugBank: Curcumin (DB11672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin is an extract from turmeric
Trial: NCT04913870
Drug: Angiotensin Receptor Blockers
RxNorm normalized name: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin Receptor Blockers treatment for 2 years.
Trial: NCT02229539
Drug: doxepin hydrochloride oral solution
RxNorm normalized name: Doxepin Hydrochloride Oral Solution
DrugBank: Doxepin (DB01142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mL (25 mg) doxepin and 2.5 mL water administered orally
Trial: NCT02229539
Drug: DLA (diphenhydramine, lidocaine and antacids) rinse
RxNorm normalized name: diphenhydramine / lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5.0 mL administered orally
Trial: NCT06180967
Drug: Midazolam Syrup
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered Orally.
Trial: NCT06180967
Drug: Midazolam Solution
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered IV bolus.
Trial: NCT06180967
Drug: Pirtobrutinib
RxNorm normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Orally.
Trial: NCT02632760
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: treatment for Iron deficient anaemia
Trial: NCT03144596
Drug: Alfuzosin Hydrochloride 10 MG
RxNorm normalized name: alfuzosin hydrochloride 10 MG
DrugBank: Alfuzosin (DB00346)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alfuzosin hydrochloride Tablet
Trial: NCT03144596
Drug: Tamsulosin Hydrochloride 0.4 MG
RxNorm normalized name: tamsulosin hydrochloride 0.4 MG
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin Hydrochloride Tablet
Trial: NCT00852358
Drug: laronidase
RxNorm normalized name: Laronidase
DrugBank: Laronidase (DB00090)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: For the treatment group, intrathecal rhIDU injections will consist of 3 cc of Aldurazyme® (laronidase) (approximately 1.74 mg) diluted with 6 cc of Elliotts B® solution for a total injection of 9 cc. The diluted enzyme will be administered via a lumbar puncture (IT) on day 0 after baseline assessments. IT injections will be repeated on days 30, 60, and 90. The subsequent doses will be administered at 3-month intervals for a total of 10 doses during the two-year period. Control patients will not receive treatment, lumbar puncture, or placebo, but will undergo all other study procedures and assessments during year one. Control patients will then enter a treatment phase consisting of four IT doses at 3-month intervals.
Trial: NCT01043575
Drug: Rifapentine
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During the first 8 weeks of therapy for TB participants \> 45 kg will receive rifapentine 600 mg orally given 5 per week and for participants \< 45 kg participants will receive 450 mg orally given 5 days per week